Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today
Three Additional Data Announcements Expected in 2023Completed Enrollment in Phase 2b VOYAGE Study of VK2809 for NASH and Fibrosis; Data Expected in... | April 26, 2023

Related Keywords

,Therapeutics Inc ,Ligand Pharmaceuticals Incorporated ,Twitter ,Prnewswire Viking Therapeutics Inc ,Exchange Commission ,Nasdaq ,Additional Data Announcements Expected ,Data Expected ,Placebo Adjusted Mean Weight Loss ,Promising Safety ,Evaluating Highly Differentiated Oral Formulation ,Results Expected ,Public Offering ,Common Stock Raising Gross Proceeds ,Quarter Ended March ,Brian Lian ,Announce Data ,Evaluating Oral Formulation ,Successful Offering ,Common Stock ,Raising Gross Proceeds ,Viking Therapeutics ,Ligand Pharmaceuticals ,Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Months Ended ,Nc Stock Exchange ,News ,Information ,Press Release ,Conference ,Wall ,Cheduled ,Or ,Dditional ,Data ,Nnouncements ,Xpected ,N ,023completed ,Enrollment ,Hase ,Tb ,Oyage ,Study ,F ,K2809 ,Cash ,End ,Xpected Vktx Us92686j1060 ,